Funding Dashboard
Tracking capital flow into gene editing and longevity biotech. Data covers 19 companies across CRISPR, base editing, epigenetic reprogramming, AI drug discovery, and more.
Total Capital Tracked
$20.2B
Companies Tracked
19
Public Companies
10
Private Companies
9
Top Funded Companies
Sorted by total capital raised. Gene Editing Longevity
Altos Labs
$3BPrivate
Epigenetic Reprogramming
CRISPR Therapeutics
$2.8BPublic
CRISPR-Cas9
Calico (Alphabet)
$2.5BPrivate
Aging Research
Intellia Therapeutics
$2.1BPublic
CRISPR-Cas9
Beam Therapeutics
$1.5BPublic
Base Editing
Sangamo Therapeutics
$1.5BPublic
ZFN
Editas Medicine
$1.2BPublic
CRISPR-Cas9/Cas12a
Wave Life Sciences
$1BPublic
RNA Editing
Verve Therapeutics
$900MPublic
Base Editing
Prime Medicine
$700MPublic
Prime Editing
Caribou Biosciences
$600MPublic
CRISPR-Cas9
Isomorphic Labs
$600MPrivate
AI Drug Discovery
Insilico Medicine
$400MPrivate
AI Drug Discovery
Unity Biotechnology
$380MPublic
Senolytics
Chroma Medicine
$335MPrivate
Epigenome Editing
Colossal Biosciences
$270MPrivate
CRISPR / Synthetic Biology
Retro Biosciences
$180MPrivate
Partial Reprogramming
NewLimit
$130MPrivate
Epigenetic Reprogramming
Turn Biotechnologies
$60MPrivate
mRNA Reprogramming
Funding by Technology
Aggregate capital raised per technology platform.
CRISPR-Cas9$5.5B27.3%
Epigenetic Reprogramming$3.1B15.5%
Aging Research$2.5B12.4%
Base Editing$2.4B11.9%
ZFN$1.5B7.4%
CRISPR-Cas9/Cas12a$1.2B6.0%
RNA Editing$1B5.0%
AI Drug Discovery$1B5.0%
Prime Editing$700M3.5%
Senolytics$380M1.9%
Epigenome Editing$335M1.7%
CRISPR / Synthetic Biology$270M1.3%
Partial Reprogramming$180M0.9%
mRNA Reprogramming$60M0.3%
Funding by Stage
Public Companies
$12.7B
10 companies
Private Companies
$7.5B
9 companies
Gene Editing vs Longevity
Gene Editing
Total Raised
$12.6B
Companies
10
Avg Funding
$1.3B
Longevity
Total Raised
$7.5B
Companies
9
Avg Funding
$836M
All Companies
| Company | Sector | Technology | Funding | Status |
|---|---|---|---|---|
| Altos Labs | Longevity | Epigenetic Reprogramming | $3B | Private |
| CRISPR Therapeutics | Gene Editing | CRISPR-Cas9 | $2.8B | Public |
| Calico (Alphabet) | Longevity | Aging Research | $2.5B | Private |
| Intellia Therapeutics | Gene Editing | CRISPR-Cas9 | $2.1B | Public |
| Beam Therapeutics | Gene Editing | Base Editing | $1.5B | Public |
| Sangamo Therapeutics | Gene Editing | ZFN | $1.5B | Public |
| Editas Medicine | Gene Editing | CRISPR-Cas9/Cas12a | $1.2B | Public |
| Wave Life Sciences | Gene Editing | RNA Editing | $1B | Public |
| Verve Therapeutics | Gene Editing | Base Editing | $900M | Public |
| Prime Medicine | Gene Editing | Prime Editing | $700M | Public |
| Caribou Biosciences | Gene Editing | CRISPR-Cas9 | $600M | Public |
| Isomorphic Labs | Longevity | AI Drug Discovery | $600M | Private |
| Insilico Medicine | Longevity | AI Drug Discovery | $400M | Private |
| Unity Biotechnology | Longevity | Senolytics | $380M | Public |
| Chroma Medicine | Gene Editing | Epigenome Editing | $335M | Private |
| Colossal Biosciences | Longevity | CRISPR / Synthetic Biology | $270M | Private |
| Retro Biosciences | Longevity | Partial Reprogramming | $180M | Private |
| NewLimit | Longevity | Epigenetic Reprogramming | $130M | Private |
| Turn Biotechnologies | Longevity | mRNA Reprogramming | $60M | Private |
Altos LabsPrivate
Longevity|Epigenetic Reprogramming
$3B
CRISPR TherapeuticsPublic
Gene Editing|CRISPR-Cas9
$2.8B
Calico (Alphabet)Private
Longevity|Aging Research
$2.5B
Intellia TherapeuticsPublic
Gene Editing|CRISPR-Cas9
$2.1B
Beam TherapeuticsPublic
Gene Editing|Base Editing
$1.5B
Sangamo TherapeuticsPublic
Gene Editing|ZFN
$1.5B
Editas MedicinePublic
Gene Editing|CRISPR-Cas9/Cas12a
$1.2B
Wave Life SciencesPublic
Gene Editing|RNA Editing
$1B
Verve TherapeuticsPublic
Gene Editing|Base Editing
$900M
Prime MedicinePublic
Gene Editing|Prime Editing
$700M
Caribou BiosciencesPublic
Gene Editing|CRISPR-Cas9
$600M
Isomorphic LabsPrivate
Longevity|AI Drug Discovery
$600M
Insilico MedicinePrivate
Longevity|AI Drug Discovery
$400M
Unity BiotechnologyPublic
Longevity|Senolytics
$380M
Chroma MedicinePrivate
Gene Editing|Epigenome Editing
$335M
Colossal BiosciencesPrivate
Longevity|CRISPR / Synthetic Biology
$270M
Retro BiosciencesPrivate
Longevity|Partial Reprogramming
$180M
NewLimitPrivate
Longevity|Epigenetic Reprogramming
$130M
Turn BiotechnologiesPrivate
Longevity|mRNA Reprogramming
$60M